DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here

    Landscape & Forecast of Uterine Fibroids

    Heavy menstrual bleeding, pelvic pressure, and infertility are the main clinical manifestations linked to uterine fibroids. Hormonal contraceptives, including coformulated estrogen and progestin oral contraceptives, progestin-only birth control pills, and long-lasting levonorgestrel-releasing intrauterine system, have long been used to manage heavy menstrual bleeding (menorrhagia), but they do not reduce fibroid tumor volume or resolve bulk symptoms.

    Over the next ten years, launches of novel selective progesterone receptor regulators (SPRMs) and gonadotropin-releasing hormone (Gn-RH) antagonists will provide more efficacious medical alternatives over procedures, such as hysterectomy and myomectomy, in the long-term management of uterine fibroids.

    Key questions we answer:

    • How will the launches of SPRMs and Gn-RH antagonists impact the use of hormonal contraceptives, tranexamic acid, NSAIDs, and procedures in patients with symptomatic uterine fibroids?
    • How will emerging SPRMs be differentiated and positioned in the Uterine Fibroids market? Which emerging SPRM will enjoy the greatest clinical and commercial success by 2026?
    • What clinical role will second-generation, oral Gn-RH antagonist therapies play in the management of uterine fibroids?
    • What are clinical advantages of SPRMs and Gn-RH antagonists, respectively, compared with Gn-RH agonists, in the long-term and preoperative management of symptomatic uterine fibroids?